학술논문
Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study.
Document Type
Article
Author
Source
Subject
*TUBERCULOSIS
*MEDICATION safety
*PSORIASIS
*DRUG efficacy
*INFECTION
*
*
*
*
Language
ISSN
0954-6634
Abstract
A recent study evaluated the safety and effectiveness of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis (TB) infection. The study included 16 patients who received IL-23 inhibitors, such as risankizumab, guselkumab, and tildrakizumab. All patients achieved at least a 75% reduction in Psoriasis Area and Severity Index (PASI) score, with 62.5% achieving complete skin clearance. No evidence of TB reactivation or serious adverse events were observed during the study. Previous clinical trials and real-life experiences also support the safety of IL-23 inhibitors in patients with TB infection. [Extracted from the article]